Takeda reports flat profit as Vyvanse generics take toll

Japanese drugmaker Takeda (TYO: 4502) posted revenue of 4.58 trillion yen ($31.7 billion) for the fiscal year ended March 31, 2025, up 7.5% on a reported basis, while core operating profit rose 10% to $8 billion. Earnings per share slipped 26% to $0.45 as net profit fell to $748 million.

Gains in key business areas — including oncology, gastrointestinal therapies, plasma-derived products and rare diseases — helped lift revenue, with strong demand for Entyvio (vedolizumab), Takhzyro (lanadelumab), and new launches such as Fruzaqla (fruquintinib) and Qdenga (dengue vaccine).

However, the falloff in sales of Vyvanse (lisdexamfetamine) due to generic competition in the USA offset some of these gains. Takeda’s neuroscience segment was down nearly 10%, driven by the Vyvanse decline.